All News Releases

Johnson & Johnson Vision Launches New Innovative Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meeting

Johnson & Johnson VISION logo
  • Johnson & Johnson Vision to launch TECNIS Synergy™ Toric II, a Continuous-Range-of-Vision Intraocular Lens (IOL) with exceptional rotational stability1, as well as CATALYS™ System cOS 6.0 software, which offers new features for astigmatism management workflow for surgeons using the CATALYS™ Precision Laser System
  • Johnson & Johnson Vision to also present first post-marketing clinical research findings on TECNIS Synergy™and TECNIS Toric II Platform

Amsterdam, The Netherlands (28 September, 2020) – Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, will launch TECNIS Synergy™ Toric II IOL with the TECNIS Simplicity™ Delivery System, a Continuous-Range-of-Vision Intraocular Lens (IOL) with exceptional rotational stability1 at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. 

In addition, the company will present the first post-marketing clinical researching findings on TECNIS Synergy™ and the TECNIS Toric II platform, as well as additional clinical outcomes and field advancing studies. Johnson & Johnson Vision will also launch CATALYS™ System cOS 6.0 software, which offers new features for astigmatism management workflow for surgeons using the CATALYS™ Precision Laser System. 

“We are very excited to launch TECNIS Synergy™ Toric II at ESCRS 2020 and to bring this important innovation to cataract patients with astigmatism,” said Rajesh Rajpal, M.D., Chief Medical Officer and Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision. “We are also pleased to present the first post-marketing clinical research studies on both TECNIS Synergy™ and the TECNIS Toric II platform. Surgeon feedback on the patient benefits of these technologies has been very strong. Johnson & Johnson Vision is committed to advancing clinically meaningful products for patients and ophthalmologists around the world.”

“At Johnson & Johnson Vision we are always striving to improve the standard of care for cataract patients,” said Erin McEachren, Regional Vice President, Europe, Middle East & Africa, Johnson & Johnson Surgical Vision. “We are excited to be unveiling virtually our new portfolio of products, from our latest toric IOL, the TECNIS Synergy™ Toric II, which offers our most advanced solution to cataract patients with astigmatism in a preloaded delivery system, to our latest software development, CATALYS™ System cOS 6.0, that allows for better accuracy, speed and ease of use for a whole range of astigmatism procedures.”

“Despite the congress being virtual this year, we will be presenting a range of new data findings and hosting several educational events within our first J&J Vision Virtual Lighthouse, which will focus on fostering community collaboration and provide a virtual space for networking, knowledge sharing, and showcasing J&J’s innovative portfolio of products.”

First Post-Marketing Clinical Trial Data for TECNIS Synergy IOL and TECNIS Toric II Platform:

  • Post-Market Evaluation of Surgeon Feedback on TECNIS Toric II Intraocular lens. D.Chang
    This prospective, multicenter, single-arm, open-label clinical study measured surgeon feedback from TECNIS Toric II 1-Piece IOL implantations in the U.S. Surgeons rated their confidence level in controlling IOL position following implantation and satisfaction with overall clinical outcomes, rotational stability as well as overall clinical performance. Overall responses at 1 week showed that the majority of surgeons were extremely or quite confident in controlling lens position and rotational stability. 
     
  • Depth of Focus, Visual Outcomes, and Spectacle Independence of a New Diffractive Presbyopia-Correcting Intraocular Lens. A. Villarrubia
    This prospective, bilateral, multi-center clinical trial compared the performance of TECNIS Synergy IOL, with its continuous high-contrast vision from far through near, against a trifocal IOL (model TFNT00).  In the trial, adults requiring cataract surgery or refractive lensectomy were randomized 2:1 to TECNIS Synergy  IOL or the trifocal.  Interim data from 83 subjects were available at three months of the 12-month study. More than 90 percent of patients receiving the TECNIS Synergy  IOL reported that they did not wear glasses overall or for far, intermediate, or near distances, in contrast to patients with the trifocal IOL (less than 90 percent at each distance).

Additional Johnson & Johnson Vision Scientific Abstracts at ESCRS include:

J&J Vision’s Activities at ESCRS at the J&J Virtual Lighthouse:

Throughout the meeting, the company will host a series of educational and interactive sessions aimed at sparking conversation and providing an opportunity to share, discuss and learn from leading experts in the field of ophthalmology. These include:  

  • EuroTimes Satellite Education Program – “Beyond Functional Vision – Turning IOL visual performance into real patient benefits” Webinar, 3rd October 2020, 13:00 – 14:00 h CET
    Chairperson: Prof. Filomena Ribeiro (PT) / Speakers: Prof. Filomena Ribeiro (PT), Prof. Tobias Röck (DE), Prof. Ulrich Schiefer (DE), Dr. Judith Ungewiss (DE), Dr. Francesco Carones (IT)
     
  • EuroTimes Satellite Education Program – “Keys to success with today’s presbyopia and toric lens technologies” Webinar, 3rd October 2020
    Speakers: Prof. Filomena Ribeiro (PT), Prof. Ulrich Schiefer (GER), Dr. Francesco Carones (IT)

https://jjsv-followthelight.azurewebsites.net/

About Cataracts and Presbyopia

Cataracts are the leading cause of blindness globally2. More than 90 percent of people develop cataracts by age 653. Left untreated, cataracts cause vision to deteriorate over time. Cataract surgery is the most common surgery performed around the world,4 including more than 4 million times in the EU in 20165.

Many people who have cataracts experience other problems with their vision, such as presbyopia. Cataract surgery is a unique opportunity to address presbyopia without an additional procedure. Presbyopia is a progressive eye condition, which makes it difficult to focus on close objects and usually becomes noticeable around 40 years of age6.

About Johnson & Johnson Vision*

At Johnson & Johnson Vision, a division of the Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, and live better. Visit us at www.jjvision.com. Follow @JNJVision on Twitter and Johnson & Johnson Vision on LinkedIn.

About Johnson & Johnson Medical Devices Companies**

At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives.  Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

** The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.  

# # #

For further information, contact:

Media contacts: 

EUROPE

Sally Hetherington

Leader, EMEA
Communications

Johnson & Johnson Vision

+44 7770 337800 (mobile)

SHether1@its.jnj.com 

Amy Murray
FleishmanHillard Fishburn
+44 7393829035 (mobile)
Amy.Murray@fhflondon.co.uk 

UNITED STATES

Erin Wolf Valich
Johnson & Johnson Vision
718-730-2192
ewolfval@its.jnj.com

John Lacey (R&D)
Johnson & Johnson Vision
781-392-5514 (mobile)
jlacey1@its.jnj.com

Jamie Hall
Pascale Communications, LLC
724-417-0167 (mobile)
jamie@pascalecommunications.com

References

  1. DOF2019OTH4015 – Study NXGT-103-MER3 - Proof of Concept Study for Next Generation IOL Models MER003 and MER004. Accessed September 2020
  2. World Health Organization - Priority Eye Diseases. REF2016OTH0004.
  3. University of Michigan Kellogg Eye Center website. http://www.kellogg.umich.edu/patientcare/conditions/cataract.html. Accessed September 2020. REF2016OTH0327.
  4. Trikha S, et al. The Journey to Femtosecond Laser-Assisted Cataract Surgery: New Beginnings or False Dawn? Eye 2013;27:461-473. REF2015OTH0014.
  5. Eurostat - Surgical operations and procedures statistics. https://ec.europa.eu/eurostat/statistics-explained/index.php/Surgical_operations_and_procedures_statistics#In-patient_procedures:_cataract_surgery. Accessed September 2020. REF2018CT4377.
  6. American Optometric Association. Presbyopia. American Optometric Association (AOA) Web site. https://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/presbyopia. Accessed September 2020. REF2019CT4316.
All News Releases